Condition: Head and Neck Neoplasms · MSI-H Cancer · Melanoma · Sponsor: University Medical Center Groningen
In this open label phase II trial combination therapy with the anti-PD-L1 antibody atezolizumab and the anti-TIGIT antibody tiragolumab will be investigated in patients with localized HNSCC who will undergo surgery, advanced or metastatic MSI-H cancer, PD-1 resistant metastatic melanoma, and patients with a locally advanced or metastatic solid tumor who, in the opinion of the investigator, based on available clinical data, may benefit from treatment with anti-PD-L1 and anti-TIGIT immunotherapy.
This description comes directly from the study's public registry record.
Derk JA de Groot, Md PhD · +31503612821 · d.j.a.de.groot@umcg.nl
Daan G Knapen, MD · +31503612821 · d.g.knapen@umcg.nl
Always discuss trial participation with your own doctor first.
| University Medical Center Groningen | Groningen, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05483400